Japan's drug majors post mixed financial results

31 July 2012

Japan’s leading drugmakers rolled out financial results for the first fiscal quarter of 2013, ended June 2012, showing mixed performances in sales and profits achieved in the period.

Takeda Pharmaceutical (TYO: 4502), Japan’s largest pharma company, announced a 12% increase in revenues to 398 billion yen ($11.93 billion) and a 16% increase in reported earnings per share to 110.9 yen. Earnings were helped by a one-off tax refund of 57 billion yen. The adjusted EPS fell 30% to 77.34 yen.

Takeda maintained its forecasts for operating profit and revenue for the full fiscal year unchanged at 160 billion yen and 1,550 billion yen, respectively. The company further estimates its FY 2015 net income to dip to 120 billion yen, as the generic version of its blockbuster Actos (pioglitazone) type 2 diabetes treatment commences in August.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK